SJG-136
SJG-136 is a pharmaceutical drug with 4 clinical trials. Historical success rate of 50.0%.
Success Metrics
Based on 2 completed trials
Phase Distribution
Phase Distribution
3
Early Stage
1
Mid Stage
0
Late Stage
Highest Phase Reached
Phase 2Trial Status & Enrollment
50.0%
2 of 4 finished
50.0%
2 ended early
0
trials recruiting
4
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
SJG-136 in Treating Patients With Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer That Did Not Respond to Previous Treatment With Cisplatin or Carboplatin
SJG-136 in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed By Surgery
SJG-136 in Treating Patients With Advanced Solid Tumors
SJG-136 in Treating Patients With Relapsed or Refractory Acute Leukemia, Myelodysplastic Syndromes, Blastic Phase Chronic Myelogenous Leukemia, or Chronic Lymphocytic Leukemia
Clinical Trials (4)
SJG-136 in Treating Patients With Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer That Did Not Respond to Previous Treatment With Cisplatin or Carboplatin
SJG-136 in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed By Surgery
SJG-136 in Treating Patients With Advanced Solid Tumors
SJG-136 in Treating Patients With Relapsed or Refractory Acute Leukemia, Myelodysplastic Syndromes, Blastic Phase Chronic Myelogenous Leukemia, or Chronic Lymphocytic Leukemia
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4